Subject Index
Coagulation Factors and Inhibitors
Fibrinolysis, fibrinogen, fibrin
Haemorrhagic Disorders
Invited
Other
Platelets
Thrombotic Disorders and antithrombotic therapy
Vascular Biology
Thrombotic Disorders and antithrombotic therapy
Animal and experimental models
Antiphospholipid antibodies
Cancer and thrombosis
Cerebrovascular disease
Clinical trials: antiplatelet agents
Clinical trials: direct antithrombin agents
Clinical trials: fibrinolytic therapy
Clinical trials: heparins/LMWH
Clinical trials: oral anticoagulants
Diabetes and metabolic disorders
DVT and pulmonary embolism
Familial thrombosis
Gene therapy
Genetic determinants and epidemiology
Homocysteine
Hormone, pregnancy
Hypercoagulability
Inflammation, infection and immunity
Ischaemic heart disease
New antithrombotic agents and approaches
New intravascular devices
Other thrombotic disorders and antithrombotic therapy
Polymorphism and arterial disease
TTP and HUS
A phase I/II trial of AAV-mediated, liver-directed gene transfer for hemophilia B
Manno C. S., Glader B., Hutchison S., Dake M., Razavi M., Herzog R. W., Mcclelland A., Rustagi P., Johnson F., Rasko J. E. J., Hoots K., Blatt P., Leonard D. G. B., Addya K., Konkle B., Chew A., Couto L. B., Arruda V. R., Kaye R., Ozelo M. C., Pierce G., High K. A., Kay M. A.
Developing hematopoietic stem cells as targets for gene therapy of hemophilia A
Tonn T., Herder C., Becker S., Grez M., Seifried E.
Fibrinogen – a new tool for gene delivery
Stemberger A., Hacker C., Plank C., Brandt S.
Gene therapy for hemophilia A with high-capacity adenoviral vectors: preclinical evaluation in hemophilic mice and dogs
Vandendriessche T., Schiedner G., Thorrez L., Brown B., Lillicrap D., Van Rooijen N., Collen D., Kochanek S., Chuah M.
Hemophilia A gene therapy using the third-generation lentiviral vector – Mouse model
Yamanouchi M., Naka H., Sakurai Y., Tanaka I., Shima M., Matsumura R., Sakata Y., Yoshioka A.
Human factor IX expression in megakaryocytes derived from electrophorated human hematopoietic cells
Dargaud Y., Rodriguez M. H., Enjolras N., Plantier J. L., Negrier C.
Improving efficacy of gene therapy of hemophilia B by the use of mutant FIX variants
Schuettrumpf J., Herzog R. W., Kaufhold A., Stafford D. W., High K. A., Arruda V. R.
Involvement of VEGF-C/flt-4 system in therapeutic angiogenesis of FGF-2 gene transfer in murine ischemic hind limb
Onimaru M., Yonemitsu Y., Tanii M., Tsutsumi T., Nakagawa K., Nakashima Y., Sueishi K.
Lineage-specific correction of a hemorrhagic disorder affecting platelets: gene therapy for Glanzmann thrombasthenia
Wilcox D. A., Hodivala-Dilke K. M., Johnson B. D., Hynes R. O., White G. C.
Preparation of special proteome chip and the application in primary screening of antigens of clotting factors of clinical plasma specimens
Xiaoyu L., Zhou L.
Recombinant sendai virus-mediated intramuscular gene transfer of FGF-2 restores collateral blood perfusion of chronically ischemic rabbit hind limb, and inhibits neointimal hyperplasia of autologous femoral vein grafts
Tanii M., Yonemitsu Y. Y., Komori K. K., Shoji T. S., Maehara Y. M., Hasegawa M. H., Sueishi K. S.
The use of three hemophilia A mouse models to illustrate strain-specific differences in immune responses to FVIII protein replacement via protein infusion or adenoviral gene therapy
Rawle F. E. M., Brown B., Shi C. X., Mckinven A. J., Tinlin S., Shaw M., Hough C., Graham F., Lillicrap D. P.
Treatment of severe canine hemophilia A by helper-dependent adenoviral-mediated gene therapy
Brown B., Shi C. X., Webster S., Tinlin S., Graham F., Lillicrap D.